The FDA's Chance to Prioritize Patients Over Bureaucracy

The FDA's Opportunity: A Call for Compassion and Action

In an age where medical advancements have the potential to transform lives, the ongoing struggles faced by families dealing with rare diseases highlight a sobering reality: bureaucracy often stands in the way of hope. My 14-year-old son, Ryu, is one of those children grappling with the devastating effects of Duchenne muscular dystrophy (DMD), a terminal condition that has robbed our family of too many loved ones. As we prepare to advocate for families like ours, we find ourselves confronting an FDA that has too often prioritized regulation over compassion.

Our planned journey to Washington, D.C., to attend a Senate hearing on the FDA’s budget was not merely a bureaucratic formality; it was meant to be a chance for Ryu to engage directly with lawmakers and share his story. Unfortunately, the hearing was canceled following the departure of then-FDA Commissioner Dr. Martin Makary—a loss that reflects a broader trend of missed opportunities for patients waiting for life-saving treatments.

Dr. Makary’s tenure was marked by promises of flexibility and openness, yet his administration ultimately failed to dismantle the barriers that prevent families from accessing critical therapies. The recent restrictions on treatments for DMD follow a pattern that feels all too familiar: a system that seems to forget the lives it impacts.

In the 1990s, my brother Angelo chose to undergo a risky experimental surgery in hopes of contributing to the understanding of DMD. His bravery is a testament to the human spirit's resilience against overwhelming odds. Today, Ryu and countless others face a different battle: a system that tells them they are not eligible for the very treatments that could extend their lives and improve their quality of life.

With advancements in gene therapy like Elevidys, there is an opportunity to provide Ryu with the care he desperately needs. Yet, the FDA has made it clear that this option is not available to him because he is already in a wheelchair. This decision is not just a statistic; it is a life-altering barrier for Ryu, who deserves the same chance at a better life as any child.

As Ryu struggles with the physical limitations imposed by his condition, he remains unyieldingly optimistic about his future. His dream of becoming a Navy SEAL is more than just a childhood fantasy; it represents his indomitable spirit and the belief that he can overcome any hurdle. Yet, this hope is systematically undermined by an FDA that seems disconnected from the realities faced by patients.

It is incumbent upon us to remind our leaders in Washington that their decisions carry life-and-death consequences. Our invitation to the new FDA leadership to visit our home is an attempt to bridge the gap between policymakers and the families they impact. Understanding the daily struggles of children like Ryu should inspire urgency and empathy—qualities that have been sorely lacking.

The new FDA Commissioner has a pivotal opportunity to reset the agency's priorities. By listening to families affected by rare diseases, they can foster a culture of compassion and innovation that prioritizes patient needs over regulatory red tape. The stakes are incredibly high: every moment wasted in bureaucratic delay is a moment taken from a child’s life.

In advocating for Ryu and others like him, we seek more than just policy changes; we seek a partnership with those in power. Our government must demonstrate the courage and resolve to facilitate access to life-saving treatments. Ryu, like my brother Angelo before him, deserves the choice to fight for his life without the shadow of governmental obstruction hanging over him.

As we await the appointment of a new FDA leader, we must hold our leaders accountable. It’s time to prioritize patient voices and ensure that the FDA becomes a beacon of hope rather than a roadblock. Together, we can create a future where children like Ryu have the chance to thrive, not just survive.